Olympiad Research’s Medifast MED Stock Holding History

Olympiad Research’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,785	Closed	-$208K	–	384
2023 Q3	$208K	Buy	+2,785	New	+$247K	0.2%	253
2020 Q4	–	Sell	-1,730	Closed	-$284K	–	270
2020 Q3	$284K	Sell	1,730 -1,288	-43%	-$212K	0.14%	176
2020 Q2	$419K	Sell	3,018 -1,434	-32%	-$132K	0.3%	52
2020 Q1	$278K	Buy	+4,452	New	+$405K	0.28%	120

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Olympiad Research's MED Position: Q4 2023 in Review

Olympiad Research sold out of Medifast (MED) in Q4 2023, closing a stake of 2,785 shares — an estimated $208K sold.

Olympiad Research first reported a position in MED in Q1 2020 and held it in 4 quarters. The position peaked at $419K in Q2 2020. 216 funds tracked by Wall St. Rank hold MED as of Q4 2023.

Olympiad Research reported no remaining Medifast position as of Q4 2023 after selling out during the quarter.
Olympiad Research sold 2,785 Medifast shares in Q4 2023, an estimated $208K.
Olympiad Research first reported a position in Medifast in Q1 2020 and held it in 4 quarters.
Olympiad Research's Medifast position peaked at $419K in Q2 2020.
216 funds tracked by Wall St. Rank held Medifast as of Q4 2023.

Based on Olympiad Research's 13F filing for Q4 2023, filed 12 Feb 2024.